ST Pharm Signs 8.5 Billion KRW Oligonucleotide Therapeutics Drug Supply Contract
[Asia Economy Reporter Minji Lee] ST Pharm announced on the 10th that it has signed a supply contract for oligonucleotide therapeutic raw materials with a Europe-based global pharmaceutical company. The contract amount is 8,555.84 million KRW, which corresponds to 9.17% of last year's consolidated sales.
Hot Picks Today
!["It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052019230771274_1779272587.jpg)
"It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- [Breaking] Samsung Union "General Strike Suspended...Tentative Agreement to Be Put to Vote"
- [Report] "I Think Twice Before Going to a Store"... Starbucks '5/18 Tank Day' Controversy Grows
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The sales regions are the United States and Europe, and the contract end date is August 31, 2023.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
